Press release
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously working towards developing 85+ HER2 negative Breast Cancer treatment therapies, as per DelveInsight
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with 85+ active players working to develop 85+ pipeline treatment therapies.
• Some of the key pharmaceutical companies working to develop potential drug candidates to improve the HER2 negative Breast Cancer treatment scenario include BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, and many others.
• Essential HER2 negative Breast Cancer pipeline therapies such as BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38 and others are under development in different phases of clinical trials.
• In January 2022, Celcuity announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to the Company's lead drug candidate, gedatolisib, for the treatment of patients with HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy.
Request a sample and discover more about the HER2 negative Breast Cancer Pipeline Report offerings @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The HER2 negative Breast Cancer pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage HER2 negative Breast Cancer products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the HER2 negative Breast Cancer pipeline landscape.
HER2 negative Breast Cancer Overview
Most Breast Cancers express the Estrogen Receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. ER+/ HER2 - ve Breast Cancer includes tumors that are ER-positive and PR positive, but negative for HER2. ER+/ HER2 - ve Breast Cancer is heterogeneous and accounts for about 70% of all breast cancers. HER2" stands for human epidermal growth factor receptor 2. There are various types of breast cancer, some have hormone receptors like estrogen or progesterone (some have both) and are called ER+ or PR+ breast cancer respectively.
Find out more about the disease and HER2 negative Breast Cancer Pipeline Recent Developments @ https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
HER2 negative Breast Cancer Therapeutics Assessment
The HER2 negative Breast Cancer Pipeline report proffers an integral view of the HER2 negative Breast Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the HER2 negative Breast Cancer Pipeline Report
• Coverage: Global
• Therapeutic Assessment By HER2 negative Breast Cancer Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By HER2 negative Breast Cancer Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
• Therapeutics Assessment By HER2 negative Breast Cancer Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
• Therapeutics Assessment By HER2 negative Breast Cancer Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
• Therapeutics Assessment By HER2 negative Breast Cancer Therapies Mechanism of Action: Selective estrogen receptor degrader, Estrogen receptor alpha antagonist, Phosphoinositide 3-kinase (PI3K) inhibitor, Selective estrogen receptor degraders
• Key HER2 negative Breast Cancer Companies: BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, and many others.
• Key HER2 negative Breast Cancer Pipeline Therapies: BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38 and many others
Dive deep into rich insights for HER2 negative Breast Cancer Emerging Therapies and assessment, visit @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. HER2-Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-Negative Breast Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. HER2-Negative Breast Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Capivasertib + Fulvestrant: AstraZeneca
11. Mid Stage Products (Phase II/III)
12. Inavolisib: Roche
13. Early Stage Products (Phase I)
14. Afuresertib + Fulvestrant: Laekna
15. Preclinical and Discovery Stage Products
16. Inactive Products
17. HER2-Negative Breast Cancer Key Companies
18. HER2-Negative Breast Cancer Key Products
19. HER2-Negative Breast Cancer- Unmet Needs
20. HER2-Negative Breast Cancer- Market Drivers and Barriers
21. HER2-Negative Breast Cancer- Future Perspectives and Conclusion
22. HER2-Negative Breast Cancer Analyst Views
23. HER2-Negative Breast Cancer Key Companies
24. Appendix
For further information on the HER2-Negative Breast Cancer therapy in the pipeline, reach out @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
About US
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously working towards developing 85+ HER2 negative Breast Cancer treatment therapies, as per DelveInsight here
News-ID: 2753254 • Views: …
More Releases from DelveInsight Business Research
![Sarcoidosis Treatment Market 2032: FDA Approval, Clinical Trials, Prevalence, Therapies and Companies by DelveInsight | Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharma, Novartis, Kinevant Sciences GmbH, Foresee Pharma](https://cdn.open-pr.com/L/9/L911429416_g.jpg)
Sarcoidosis Treatment Market 2032: FDA Approval, Clinical Trials, Prevalence, Th …
DelveInsight's "Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Sarcoidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcoidosis Market Forecast
https://www.delveinsight.com/sample-request/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Sarcoidosis Market Report:
•…
![Chronic Spontaneous Urticaria Treatment Market 2034: FDA Approval, Clinical Trials, Market Size, Prevalence, Therapies and Companies by DelveInsight | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly, Genentech, Regeneron, GSK](https://cdn.open-pr.com/L/9/L911823001_g.jpg)
Chronic Spontaneous Urticaria Treatment Market 2034: FDA Approval, Clinical Tria …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria Market…
![Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Market Size, Prevalence, Therapies and Companies by DelveInsight | Eli Lilly, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG](https://cdn.open-pr.com/L/9/L911753719_g.jpg)
Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Ma …
(Albany, USA) DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends,…
![Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies, Treatment Market, ROA, MOA and Companies involved by DelveInsight](https://cdn.open-pr.com/L/9/L910722635_g.jpg)
Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA, PDMA, FDA Approval …
(Albany, USA) DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It…
More Releases for HER2
HER2 Antibodies Market Expand with Significant CAGR During 2018-2025
Global HER2 Antibodies Market: Overview
Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due…
HER2 Antibodies Market to approach US$ 21,669.1 mn by 2025
A recent market intelligence study by Transparency Market Research (TMR) suggests that the global HER2 antibodies market offers lucrative opportunities as the awareness regarding breast cancer and personalized medicines spreads. Consequently, the competitive landscape of the HER2 antibodies market is already quite intense with the presence of a large number of players, both global and regional. The report identifies Pfizer, Inc., Novartis AG, Genentech Inc. by F. Hoffmann-La Roche Ltd.,…
HER2 Antibodies Market Key Trends and Forecast Research Report 2025
As per the projections of the TMR report, the demand in the global HER2 antibodies market will multiply at an impressive CAGR of 8.6% during the forecast period of 2017 to 2025, achieving an estimated global valuation of US$21,669.1 mn by the end of 2025, substantially up from its evaluated worth of US$10,087.8 mn in 2016. In the near future, new drug development is expected to be based on adjuvant…
HER2 Antibodies Market Key Trends and Forecast Research Report 2025
As per the projections of the TMR report, the demand in the global HER2 antibodies market will multiply at an impressive CAGR of 8.6% during the forecast period of 2017 to 2025, achieving an estimated global valuation of US$21,669.1 mn by the end of 2025, substantially up from its evaluated worth of US$10,087.8 mn in 2016. In the near future, new drug development is expected to be based on adjuvant…
Her2 Antibodies Market: Industry Overview and Key Factors
Global Her2 Antibodies Market: Overview
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC).
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2…
Emerging Opportunities in Her2 Antibodies Market
Global Her2 Antibodies Market: Overview
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC).
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2…